MIRM

MirumA

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment CodexPost-earnings T+3

B+

Bull case

30%

Probability

Target price

$135.00

+46.5% vs current

Most likely

Base case

45%

Probability

Target price

$118.00

+28.0% vs current

B-

Bear case

25%

Probability

Target price

$82.00

-11.0% vs current

AI sentiment snapshot

Latest data as of 2026-05-08

AI commentary

News flow is clearly constructive into May 2026: positive VISTAS headlines on May 4 and a beat-and-raise style earnings update on May 6. Immediate reaction evidence is mixed in low-trust market summaries, but the verified tape shows MIRM closed at $102.93 on May 7, 2026 and traded at $107.16 on May 8, 2026, indicating the post-release setup remained positive. Analyst revision visibility was still limited in the checked sources, so this remains a cautious positive-monitoring view rather than a high-conviction post-earnings upgrade.

RankAlpha Sentiment Codex - 2026-05-08

Open post-earnings memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-05-06catalystQ1 2026 update raised revenue guidance and reinforced commercial executionHigh impact

Mirum’s May 6, 2026 earnings update highlighted Q1 2026 net product sales of $159.9 million, a raise in 2026 net product sales guidance to $660 million-$680 million from the prior $630 million-$650 million range, and unrestricted cash, cash equivalents and investments of $420.6 million as of March 31, 2026; the same filing also notes the update was furnished on Form 8-K and provides at least 12 months of operating runway [#8-K-2026-05-06] [#10-Q-2026-05-06].

2026-09-26eventZilurgisertib Priority Review adds a new rare-disease launch option in 2026High impact

Mirum disclosed in its March 31, 2026 10-Q that it entered an April 2026 agreement with Incyte to obtain commercialization rights to zilurgisertib upon FDA approval, and that the NDA has been accepted with a September 26, 2026 PDUFA date, creating a discrete regulatory catalyst outside the existing cholestatic liver and HDV programs [#10-Q-2026-05-06].

2026-10-31catalystBrelovitug AZURE topline data can open a 2027 BLA pathHigh impact

Mirum said on March 5, 2026 that AZURE-1 enrollment and AZURE-4 screening were complete, with topline 24-week data expected in the second half of 2026 and the two studies intended to support a U.S. BLA submission; this is one of the company’s largest pipeline value drivers but remains binary and integration-sensitive.

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-08 • Updated nightlySource: Internal modelMethodology